Randomized control trials have shown that using of anti-inflammatory agents, such as celecoxib or infliximab, can successfully improve depression outcomes in patients with elevated CRP levels and patients with treatment-resistant depression87, strongly suggesting that inflammation has a crucial role in the pathogenesis of at least certain types of depression58,87. This evidence concerns the gene CRP and depressive symptom measurement.